Clinical Trials
31 trialsNCT03878524 2024-03-04
Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial
OHSU Knight Cancer Institute
Phase 1 Terminated
NCT01238692 2023-03-24
A Phase II Study of Oral Panobinostat (LBH589) and Rituximab to Treat Diffuse Large B Cell Lymphoma (DLBCL)
Jewish General Hospital
Phase 2 Completed
NCT01261247 2022-05-24
Panobinostat in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma
Mayo Clinic
Phase 2 Completed
NCT00425555 2021-08-20
Study of Oral LBH589 in Adult Patients With Refractory Cutaneous T-Cell Lymphoma
Novartis
Phase 2 Completed
NCT00490776 2021-08-18
Study of Oral LBH589 in Adult Participants With Refractory/Resistant Cutaneous T-Cell Lymphoma (CTCL)
Novartis
Phase 2 Terminated
NCT00742027 2021-07-28
Phase II Study of Oral Panobinostat in Adult Participants With Relapsed/Refractory Classical Hodgkin's Lymphoma
Novartis
Phase 2 Completed
NCT00936611 2021-01-28
LBH589 in Relapsed or Relapsed and Refractory Waldenstrom's Macroglobulinemia
Dana-Farber Cancer Institute
Phase 2 Completed
NCT01169636 2021-01-06
Panobinostat Plus Ifosfamide, Carboplatin, and Etoposide (ICE) Compared With ICE For Relapsed Hodgkin Lymphoma
M.D. Anderson Cancer Center
Phase 1/2 Completed
NCT00621244 2021-01-05
A Study of Oral LBH589 in Adult Patients With Advanced Hematological Malignancies
Novartis
Phase 1/2 Completed
NCT00503451 2020-12-19
A Study to Investigate the Effects of Ketoconazole on LBH589 in Patients With Advanced Solid Tumors
Novartis
Phase 1 Completed
NCT00918333 2020-03-10
Panobinostat and Everolimus in Treating Patients With Recurrent Multiple Myeloma, Non-Hodgkin Lymphoma, or Hodgkin Lymphoma
Mayo Clinic
Phase 1/2 Completed
NCT01523834 2019-11-22
FIL_PanAL10
Fondazione Italiana Linfomi - ETS
Phase 2 Completed
NCT02518750 2019-04-03
Re-Induction Therapy for Relapsed Pediatric T-Cell Acute Lymphoblastic Leukemia or Lymphoma
St. Jude Children's Research Hospital
Phase 2 Terminated
NCT01341834 2018-04-24
Safety and Tolerability Study of RAD001 and LBH589 in All Solid Tumors With Enrichment for EBV Driven Tumors
National Cancer Centre, Singapore
Phase 1 Unknown
NCT01460940 2017-11-14
A Phase II Trial of Panobinostat and Lenalidomide in Patients With Relapsed or Refractory Hodgkin's Lymphoma
Ohio State University Comprehensive Cancer Center
Phase 2 Completed
NCT01282476 2017-05-09
Panobinostat With Rituximab for Relapsed/Refractory Diffuse Large B Cell Lymphoma
Massachusetts General Hospital
Phase 2 Terminated
NCT02961816 2017-04-21
Panobinostat Combined With High-Dose Gemcitabine/Busulfan/Melphalan With Autologous Stem Cell Transplant for Patients With Refractory/Relapsed Lymphoma
M.D. Anderson Cancer Center
Phase 2 Withdrawn
NCT01032148 2017-01-12
Study of LBH589, A Deacetylase Inhibitor in Patients With Recurrent or Refractory Hodgkin or Non-Hodgkin's Lymphoma
Roswell Park Cancer Institute
Phase 1 Terminated
NCT00978432 2016-11-25
Epigenetic Modulation in Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
Duke University
Phase 2 Terminated
NCT01034163 2016-07-07
PATH
Novartis
Phase 3 Completed
NCT01321346 2015-11-24
A Study Of Panobinostat In Children With Refractory Hematologic Malignancies
Therapeutic Advances in Childhood Leukemia Consortium
Phase 1 Completed
NCT00967044 2015-02-26
Panobinostat (LBH589) Plus Everolimus (RAD001) in Patients With Relapsed and Refractory Lymphoma
M.D. Anderson Cancer Center
Phase 1/2 Completed
NCT01504776 2014-09-19
BUS48T
Augusta University
Phase 1 Completed
NCT00723203 2014-09-09
Panobinostat in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia or Acute Myeloid Leukemia
City of Hope Medical Center
Phase 2 Terminated
NCT00901147 2014-06-27
Study of Bortezomib and Panobinostat in Treating Patients With Relapsed/Refractory Peripheral T-cell Lymphoma or NK/T-cell Lymphoma
Singapore General Hospital
Phase 2 Completed
NCT01884428 2014-01-29
Study of Combination of PIGEV Before Autologous Stem Cell Transplant in Patients With Hodgkin's Lymphoma
Istituto Clinico Humanitas
Phase 1 Unknown
NCT01090973 2013-12-16
Oral LBH589 in Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) and Mantle Cell Lymphoma (MCL)
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Terminated
NCT00962507 2013-02-15
Panobinostat and Everolimus in Treating Patients With Relapsed or Refractory Lymphoma or Multiple Myeloma
City of Hope Medical Center
Phase 1 Completed
NCT00412997 2012-11-27
LBH589 in Adult Patients With Advanced Solid Tumors or Cutaneous T-cell Lymphoma
Novartis
Phase 1 Completed
NCT00699296 2012-11-27
Study of Oral LBH589 in Patients With Cutaneous T-cell Lymphoma and Adult T-cell Leukemia/Lymphoma
Novartis
Phase 2 Terminated
NCT00472368 2012-05-01
A Study to Determine the Absorption, Distribution, Metabolism, and Excretion of LBH589
Novartis
Phase 1 Completed